先为达生物

Sciwind Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases. The company's lead candidate, XW003 (ecnoglutide), is a long-acting GLP-1 analog currently in Phase 3 clinical trials for the treatment of type 2 diabetes and obesity. Sciwind's pipeline also includes oral formulations of GLP-1 receptor agonists and multi-receptor agonists targeting GLP-1, GIP, and glucagon receptors. Leveraging its proprietary peptide engineering and delivery technologies, the company aims to provide more effective and convenient treatment options for patients worldwide. Sciwind maintains research and development facilities in both China and the United States to support its global clinical development strategy.